Qiming Venture Partners

Qiming Venture Partners is a highly influential venture capital firm established in 2006, primarily focusing on early and growth-stage investments within the Technology & Consumer and Healthcare sectors. Headquartered in Shanghai, China, with additional offices in Beijing, Suzhou, Shenzhen, and Hong Kong, Qiming maintains a strong focus on the Greater China region, while also having a presence in the US. The firm has solidified its position as one of the leading VCs in Asia, managing substantial capital and a diverse portfolio of innovative companies.

As of early 2023, Qiming Venture Partners manages over $9.4 billion in assets across a combination of 12 USD-denominated funds and 8 RMB-denominated funds, highlighting its significant financial capacity and global reach. Its investment strategy is centered on identifying and nurturing high-growth potential companies, often serving as the initial institutional investor or a key early-stage backer. The firm's deep industry expertise, extensive network, and hands-on approach provide considerable strategic value to its portfolio companies, aiding their development and expansion.

Qiming's portfolio is extensive, comprising over 500 companies. The firm boasts an impressive track record of successful exits, with more than 180 portfolio companies having completed IPOs on various global stock exchanges, and over 70 achieving successful M&A exits. Notable investments include industry leaders such as Xiaomi, Meituan, Bilibili, Gan & Lee Pharmaceuticals, Zai Lab, and CanSino Biologics, demonstrating its consistent ability to identify and support future market leaders across its target sectors. This strong performance underscores Qiming's reputation as a top-tier venture capital firm in the Asian market.